ONCOMARK LIMITED

Their core work

OncoMark is an Irish SME developing prognostic assays for cancer, with their flagship work focused on early-stage breast cancer diagnostics. They combine biomarker discovery with translational biology to create tools that help clinicians predict disease progression and tailor treatment decisions. Their involvement in training networks around melanoma and personalized medicine indicates deep expertise in omics-based cancer research. They secured substantial SME Instrument Phase 2 funding (€2.75M) for commercializing their breast cancer prognostic assay, signaling a product close to market readiness.

What they specialise in

How they've shifted over time

OncoMark's H2020 trajectory spans 2014–2016 in project start dates, a relatively short window. Their earliest involvement (MEL-PLEX, 2014) was as a participant in melanoma translational research training. By 2015–2016, they moved into personalized medicine training (TOPMed10) and then stepped up as coordinator of their own breast cancer diagnostics commercialization project (OncoMasTR). The progression shows a clear shift from contributing to others' research networks toward leading their own product development.

OncoMark is moving from research participation toward commercializing cancer diagnostic products, making them a strong candidate for partnerships that bridge clinical research and market deployment.

How they like to work

OncoMark operates across all roles — coordinator, participant, and third party — showing flexibility in how they engage with consortia. With 24 unique partners across 13 countries from just 3 projects, they work within large, internationally diverse networks rather than small focused teams. Their willingness to serve as a third party in training networks while simultaneously leading their own SME Instrument project suggests they are pragmatic collaborators who contribute specialized cancer diagnostics expertise wherever it fits.

Despite only 3 projects, OncoMark has built a wide network of 24 partners across 13 countries, reflecting the large consortium sizes typical of MSCA training networks. Their geographic reach spans broadly across Europe from their Dublin base.

What sets them apart

OncoMark stands out as one of the few Irish SMEs that secured SME Instrument Phase 2 funding for cancer diagnostics — a competitive scheme reserved for companies with strong commercialization potential. Their combination of deep cancer biology expertise (melanoma, breast cancer) with computational and omics capabilities makes them a rare bridge between academic biomarker research and market-ready diagnostic products. For consortium builders, they offer both scientific credibility through training network involvement and commercial viability proven by EU investment reviewers.

Highlights from their portfolio

• TOPMed10
  Fellowship programme in omics-driven personalized medicine connecting OncoMark to the broader precision medicine training ecosystem.
• OncoMasTR
  Their flagship: a €2.75M SME Instrument Phase 2 project to commercialize a prognostic assay for early-stage breast cancer, coordinated by OncoMark itself.
• MEL-PLEX
  Placed OncoMark within a European melanoma research training network, demonstrating their recognized expertise in cancer translational biology.